Weiss Ratings Reaffirms "Sell (D-)" Rating for Rezolute (NASDAQ:RZLT)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Rezolute (NASDAQ:RZLT), indicating caution for potential investors.
• Despite Weiss Ratings' stance, several others like Wedbush and BTIG Research have issued higher price targets and "Buy" ratings, suggesting a mixed outlook among analysts.
• Rezolute reported a quarterly loss of ($0.26) EPS, missing consensus estimates and reflecting challenges in its financial performance amid a price range of $2.21 to $9.72 over the past year.

Rezolute (NASDAQ:RZLT - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other research analysts also recently issued reports on the company. Wedbush reiterated an "outperform" rating and set a $12.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. BTIG Research restated a "buy" rating and issued a $17.00 price target on shares of Rezolute in a research note on Thursday, September 18th. Maxim Group upped their price target on Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, September 18th. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research note on Wednesday, September 3rd. Finally, Guggenheim restated a "buy" rating and issued a $15.00 price target on shares of Rezolute in a research note on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Rezolute presently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

Rezolute Stock Performance

Shares of NASDAQ:RZLT opened at $8.72 on Wednesday. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $9.72. The firm has a market cap of $791.86 million, a price-to-earnings ratio of -8.99 and a beta of 0.04. The business has a 50-day simple moving average of $7.47 and a two-hundred day simple moving average of $5.21.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). As a group, research analysts predict that Rezolute will post -0.93 earnings per share for the current year.

Institutional Trading of Rezolute

Several hedge funds have recently modified their holdings of the company. Rosalind Advisors Inc. purchased a new stake in Rezolute during the 2nd quarter valued at $7,766,000. Opaleye Management Inc. raised its holdings in Rezolute by 94.3% during the 2nd quarter. Opaleye Management Inc. now owns 903,442 shares of the company's stock valued at $4,029,000 after buying an additional 438,442 shares during the period. Massar Capital Management LP purchased a new stake in Rezolute during the 2nd quarter valued at $126,000. BNP Paribas Financial Markets purchased a new stake in Rezolute during the 2nd quarter valued at $25,000. Finally, Boothbay Fund Management LLC raised its holdings in Rezolute by 1,745.6% during the 2nd quarter. Boothbay Fund Management LLC now owns 266,671 shares of the company's stock valued at $1,189,000 after buying an additional 252,222 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.